ESMO Real World Data and Digital Oncology最新文献

{"title":"Feasibility of Wave Health to monitor electronic patient-reported outcomes (ePROs) in prostate cancer patients","authors":"B. Gomez Mediavilla ,&nbsp;B. Congregado ,&nbsp;E. Linares Espinos ,&nbsp;I. Rivero Belenchon ,&nbsp;L. Basterretxea ,&nbsp;G. Sancho ,&nbsp;N. Lainez ,&nbsp;D. Buchser ,&nbsp;T. Leturgez ,&nbsp;A.A. Schmitz ,&nbsp;J. Pozueta ,&nbsp;I. Gurruchaga ,&nbsp;D. Cacho Lavin ,&nbsp;B. Esteban ,&nbsp;A. Hernandez ,&nbsp;M. Lashey ,&nbsp;F. Sanguedolce ,&nbsp;I. Duran","doi":"10.1016/j.esmorw.2025.100177","DOIUrl":"10.1016/j.esmorw.2025.100177","url":null,"abstract":"<div><h3>Background</h3><div>Benefits of electronic patient-reported outcomes (ePROs) are well established, but concerns exist around their applicability in certain cancer patient populations. This multicenter study aimed to evaluate the feasibility and compliance of a novel platform, Wave Health, to automate the collection of ePROs among patients undergoing systemic treatment for prostate cancer.</div></div><div><h3>Patients and methods</h3><div>The study was conducted across eight Spanish hospitals where prostate cancer patients able to use smartphones were asked to download the Wave Health app and fill out different ePRO questionnaires weekly for 12 weeks. The primary outcome was compliance with questionnaire completion.</div></div><div><h3>Results</h3><div>Eighty-seven patients were enrolled (48% aged &gt;70 years; 48% &gt;high school educated). The compliance rate using the app was 93.3% to complete 19 scheduled ePRO questionnaires during their participation, and the acceptance rate was 94.3%. Most patients described the app as intuitive and completed most ePROs (&gt;80%) ‘without help’, even though 28.7% reported a lack of technology confidence. The mean Cancer Health Literacy Test-30-Spanish (CHLT-30-DKspa) score increased from 22.3 at baseline to 23.2 at week 12. Fatigue, weakness, and poor sleep were the most common symptoms reported by patients. Most health care providers (97.6%) rated the platform as ‘very useful,’ ‘useful,’ or ‘somewhat useful.’</div></div><div><h3>Conclusion</h3><div>This study demonstrated that ePRO collection via the Wave Health platform is feasible, with high rates of compliance, acceptance, and satisfaction among prostate cancer patients under systemic treatment regardless of age, education, or level of tech confidence, and that the app is perceived as useful among health care providers.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"10 ","pages":"Article 100177"},"PeriodicalIF":0.0,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: the COALA project","authors":"N. Hitchen ,&nbsp;H.-L. Wong ,&nbsp;R. Wong ,&nbsp;J. Shapiro ,&nbsp;M. Burge ,&nbsp;L. Nott ,&nbsp;B. Lee ,&nbsp;S.H. Lim ,&nbsp;S.F. Wong ,&nbsp;S. Caird ,&nbsp;V. Wong ,&nbsp;N. Rainey ,&nbsp;A. Khattak ,&nbsp;H. Mandaliya ,&nbsp;T. Hayes ,&nbsp;J. Torres ,&nbsp;A. Jalali ,&nbsp;A. Campbell ,&nbsp;P. Gibbs ,&nbsp;J. Tie","doi":"10.1016/j.esmorw.2025.100178","DOIUrl":"10.1016/j.esmorw.2025.100178","url":null,"abstract":"<div><h3>Background</h3><div>BRAF^V600E-mutated metastatic colorectal cancer (mCRC) is a biologically distinct and clinically aggressive subtype associated with poor outcomes. Real-world data on this population remains limited, particularly within the Australian health care setting.</div></div><div><h3>Patients and methods</h3><div>The COALA study is a national, prospective registry-based observational analysis of patients with mCRC across 21 Australian institutions. Data were extracted from the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) and TRACC-Select registries and included demographics, molecular profiles, treatment patterns and overall survival (OS). Uptake and impact of encorafenib plus cetuximab (EC), since being available in Australia from May 2019, were examined.</div></div><div><h3>Results</h3><div>Of 2976 patients tested for <em>BRAF</em>, 374 (13%) harboured BRAF^V600E mutations, including 53 (24%) of the 217 ‘very-young’ subset (&lt;40 years of age). Overall, compared with wild-type (<em>BRAF</em>-wt) tumours, BRAF^V600E-mutated tumours were more likely to occur in females (55% versus 39%), and right-sided primaries (60% versus 28%) occur with deficient mismatch repair (dMMR) (24% versus 3%), and/or peritoneal metastases (36% versus 20%). Only 42% of BRAF^V600E patients received second-line (2L) treatment. OS was significantly shorter in BRAF^V600E versus <em>BRAF</em>-wt patients [hazard ratio (HR) 1.75, 95% confidence interval 1.5-2; median 16.6 versus 32.3 months]. Among BRAF^V600E patients receiving 2L therapy, EC use versus chemotherapy was associated with a trend for improved OS (HR 0.70, median 8.6 versus 6.8 months).</div></div><div><h3>Conclusions</h3><div>The COALA study provides the first Australian real-world profile of BRAF^V600E-mutated mCRC. These findings underscore the importance of early and effective therapeutic strategies, and identify a novel, disproportionately affected very-young subgroup requiring targeted research and clinical focus.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100178"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing accessibility and impact of digitally enabled clinical trials: the WeShare engagement and equity toolkit","authors":"M.A. Franzoi ,&nbsp;S. Everhard ,&nbsp;E. Gillanders ,&nbsp;I. Vaz-Luis","doi":"10.1016/j.esmorw.2025.100175","DOIUrl":"10.1016/j.esmorw.2025.100175","url":null,"abstract":"<div><div>Digital technologies are advancing rapidly, reshaping the way we design, operate, and execute clinical trials. Digitally enabled trials are particularly well-positioned to accelerate the implementation of oncology research by streamlining key clinical trial processes such as screening, recruitment, consent, data collection, follow-up, and intervention delivery. Ensuring engagement and addressing equity concerns are critical to the success of these trials, especially if the goal is for digital health to act as an equalizer, reducing existing and persistent disparities in oncology care. This perspective emphasizes the development and implementation of a comprehensive toolkit to tackle engagement and equity challenges within digitally enabled clinical trials.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100175"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144921296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editoiral Board","authors":"","doi":"10.1016/S2949-8201(25)00079-7","DOIUrl":"10.1016/S2949-8201(25)00079-7","url":null,"abstract":"","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100190"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145095265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benchmarking cancer outcomes in Europe: a scoping review of methodologies and case-mix adjustments","authors":"J. Thurell ,&nbsp;L. Doppelbauer ,&nbsp;E.M. Verheul ,&nbsp;I. Petrov ,&nbsp;M.M. Karsten ,&nbsp;L.B. Koppert ,&nbsp;J. Bergh ,&nbsp;I. Fredriksson ,&nbsp;P. Lindgren ,&nbsp;N. Kiani ,&nbsp;E. Hedayati","doi":"10.1016/j.esmorw.2025.100176","DOIUrl":"10.1016/j.esmorw.2025.100176","url":null,"abstract":"<div><h3>Background</h3><div>Benchmarking hospital outcomes is crucial for identifying inequities and improving cancer care. Meaningful comparisons require selecting relevant outcomes and adjusting for case-mix factors such as age, comorbidity, and stage. Without case-mix adjustment, hospitals may be unfairly assessed based on patient mix rather than care quality. No prior review has examined benchmarking practices in European cancer care. This scoping review addresses: (i) Which health outcomes are frequently benchmarked? (ii) What case-mix factors are commonly used for adjustment? (iii) Which statistical approaches are utilized? (iv) How are case-mix models developed and evaluated?</div></div><div><h3>Materials and methods</h3><div>We conducted a systematic scoping review searching OVID MEDLINE, Web of Science, and EMBASE. Eligible studies focused on benchmarking populations with a cancer diagnosis, involved European hospitals, and evaluated health outcomes like survival. Abstract screening and full-text appraisal were done independently by two authors. Data were extracted into a pre-specified matrix, and results synthesized by research question.</div></div><div><h3>Results</h3><div>After screening 4953 abstracts, 65 studies were included. Key gaps include a lack of validated case-mix models, under-representation of long-term outcomes, and a tendency to ‘over-adjust’ by including treatment factors in case-mix models, potentially obscuring true differences in performance. Regression modeling remains the gold standard for adjustment. A consensus is needed on reporting and evaluating case-mix models, akin to TRIPOD guidelines.</div></div><div><h3>Conclusions</h3><div>A shift toward standardized, validated benchmarking practices is essential to drive health care improvements. Only through rigorous methodologies, standardized reporting, and international collaboration can hospital benchmarking become a transformative tool for improving cancer care quality and patient outcomes.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100176"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing standards: harmonising coding principles for a minimal cancer dataset in the OMOP Common Data Model","authors":"A. Ajmal ,&nbsp;O. Bouissou ,&nbsp;J. Brash ,&nbsp;S. Cheeseman ,&nbsp;P.G. Banduge ,&nbsp;A.L. Gomes ,&nbsp;L. Revie ,&nbsp;E. Ross ,&nbsp;S. Theophanous ,&nbsp;J. Thonnard ,&nbsp;A. Van Maanen ,&nbsp;A. Vengadeswaran ,&nbsp;A. Wolf ,&nbsp;X.M. Fernandez","doi":"10.1016/j.esmorw.2025.100179","DOIUrl":"10.1016/j.esmorw.2025.100179","url":null,"abstract":"<div><h3>Background</h3><div>Analysing clinical information across a network poses challenges due to heterogeneity of data collection, storage and availability. The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) provides a standardised framework for clinical data, allowing network-level comparisons and the combination of data to enhance analytical power and increase research robustness. To capture specific oncology information across the Digital Oncology Network for Europe (DigiONE) using OMOP, we developed the Minimal Essential Description of Cancer (MEDOC) framework.</div></div><div><h3>Materials and methods</h3><div>MEDOC was developed through several iterations and was then utilised in DigiONE pilot studies. This was a community-driven process, made possible by discussions to distinguish differences in hospital data and by conducting deep-dive sessions to solve specific issues in aligning source data with the MEDOC structure.</div></div><div><h3>Results</h3><div>The initial version of MEDOC has been utilised in two DigiONE observational cancer studies to date with a further two studies in progress, and training resources including the implementation guide have been developed. Lessons learned in the development of our MEDOC to OMOP alignment include challenges in establishing diagnosis date, confirming metastasis location and tumour classification code due to granularity of available data, among other challenges specific to individual centres.</div></div><div><h3>Conclusion</h3><div>The utility of MEDOC has been evidenced in research applications and will be continually developed in line with both learnings from centres and developments in the field of oncology. The implementation of MEDOC in line with the OMOP CDM is timely, given European initiatives to harmonise health care data systems.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100179"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145018295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of digital self-management support for breast cancer survivors: ensuring evidence-based approaches and patient engagement from concept to implementation☆","authors":"M.A. Franzoi ,&nbsp;E. Martin ,&nbsp;A.R. Ferreira ,&nbsp;F. Jacq ,&nbsp;E. Gillanders ,&nbsp;A. Di Meglio ,&nbsp;I. Vaz-Luis","doi":"10.1016/j.esmorw.2025.100173","DOIUrl":"10.1016/j.esmorw.2025.100173","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to develop digital self-management programs incorporating evidence-based behavioral interventions to address the physical and psychosocial challenges faced by breast cancer survivors (BCS).</div></div><div><h3>Materials and methods</h3><div>The development was guided by the Medical Research Council framework and involved five steps: (1) needs assessment and consultations with patients and providers (focus groups and surveys), (2) ranking of priority symptoms/conditions (evaluation of patient-reported outcomes within a large cohort), (3) identification of validated self-management programs (literature review), (4) prototype design, testing, and refinement (focus groups with patients for pilot testing), and (5) formal evaluation. This study focused on steps 1-4, including both quantitative and qualitative data collection.</div></div><div><h3>Results</h3><div>In steps 1-2, six priority symptoms/conditions were identified: emotional distress, fatigue, insomnia, musculoskeletal pain, physical inactivity, and high body mass index. In steps 3-4, three digital behavioral programs were developed and tested: physical activity, mindfulness/meditation, and yoga. These programs incorporated educational content, video and podcast exercises, weekly live sessions, and moderated chat groups. During prototype testing, focus groups with 27 patients highlighted high satisfaction with the programs, noting their potential to increase access to care, empower patients, and improve symptom management. Engagement challenges were identified, including digital literacy aspects, the need for flexibility for autonomous practice, and the need for tools to boost motivation. Programs were refined and are being tested in hybrid efficacy-implementation trials.</div></div><div><h3>Conclusions</h3><div>Digital self-management programs intended to improve symptom management and quality of life for BCS were developed. By integrating evidence-based content and early patient feedback, these programs have the potential to enhance supportive care access and empower patients. Ongoing trials will assess their clinical efficacy and implementation, with an emphasis on equitable access and engagement across diverse populations.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100173"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) visualisation: picturing the evidence of clinical benefit of clinical trial data","authors":"C.G. Urzua-Traslavina ,&nbsp;N.J. Latino ,&nbsp;M. Galotti ,&nbsp;N.I. Cherny ,&nbsp;S.F. Oosting ,&nbsp;E.G.E. de Vries ,&nbsp;R.S.N. Fehrmann","doi":"10.1016/j.esmorw.2025.100171","DOIUrl":"10.1016/j.esmorw.2025.100171","url":null,"abstract":"<div><h3>Background</h3><div>Choosing the right cancer treatment is crucial for patients and health care professionals, while health care systems must allocate resources efficiently. The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) assists decision making by assessing the clinical benefit of anticancer medications. ESMO developed and field-tested a visualisation of the ESMO-MCBS scores to increase its user-friendliness and effectiveness.</div></div><div><h3>Methods</h3><div>An expert panel iteratively designed and internally reviewed a prototype of the visualisation, then refined it through field-testing. A survey was conducted concurrently with the field-testing to evaluate the understandability of the visualisation. Field-testing materials and survey questions were made accessible to the public on the ESMO website and promoted at the ESMO Congress 2019 through ESMO social media platforms. The insights gathered from all the feedback were instrumental in refining the design. Subsequently, a conclusive survey was deployed during the ESMO Congress 2023 to assess the final version of the visualisation.</div></div><div><h3>Results</h3><div>A two-panel visualisation was developed to reflect the steps of the ESMO-MCBS scoring procedure. Field-testing included visualisations for 121 studies, each based on their ESMO-MCBS scores. Feedback from the survey (<em>n</em> = 56 experts) indicated that oncology-related professions and statisticians, as well as respondents with previous knowledge of the ESMO-MCBS, showed a sufficient understanding of the visualisations while indicating areas to improve. Incorporating the survey’s feedback, the revised visualisations were then integrated into the publicly available ESMO-MCBS Scorecards, and a final survey (<em>n</em> = 118 experts) was conducted to evaluate these revisions. More than 80% of the respondents reported the visualisation to be accessible and effective at communicating the score.</div></div><div><h3>Conclusions</h3><div>The visualisations offer a visual understanding of the ESMO-MCBS scores by enhancing user-friendliness and understandability.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100171"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Data-centric artificial intelligence and cancer research: construction of a real-world head and neck treatment data repository","authors":"V. Butterworth ,&nbsp;T. Young ,&nbsp;H. Drake ,&nbsp;I. Palmer ,&nbsp;T. Avgoulea ,&nbsp;E. Ivy ,&nbsp;J. Andriolo ,&nbsp;C. Creppy ,&nbsp;C. Routledge ,&nbsp;D. Adjogatse ,&nbsp;A. Kong ,&nbsp;I. Petkar ,&nbsp;M. Reis Ferreira ,&nbsp;D. Eaton ,&nbsp;M. Lei ,&nbsp;S. Misson ,&nbsp;D. Vilic ,&nbsp;T. Guerrero Urbano","doi":"10.1016/j.esmorw.2025.100162","DOIUrl":"10.1016/j.esmorw.2025.100162","url":null,"abstract":"<div><h3>Background and purpose</h3><div>The performance and generalisability of machine learning (ML) models relies on high-quality data. Retrospective and prospective collection of high-quality data for research use while respecting data protection and patient privacy remains a challenge in the clinical environment. Currently, months of laborious extraction and clinical annotation are often necessary before data analysis can begin. We present a novel institutional federated data lake, utilising open-source software, to facilitate efficient production of ML models from head and neck cancer (HNC) imaging and radiotherapy (RT) data. This structured pipeline dramatically reduces the time associated with the production of ML models and real-world evidence generation. This paper describes our governance-compliant processes and provides a framework for establishing similar databases.</div></div><div><h3>Materials and methods</h3><div>Extensible NeuroImaging Archival Toolkit (XNAT) is a powerful open-source imaging platform. Within our department, it forms a part of the local secure enclave for the purposes of federated learning in artificial intelligence projects and provides import, archiving, processing, search and secure distribution facilities for imaging and RT data.</div></div><div><h3>Results</h3><div>We have created a clinically annotated, carefully curated, data lake of 2895 consenting HNC patients containing 22 170 relevant diagnostic, staging, treatment and monitoring imaging sets. Key recommendations for replication include infrastructure planning, robust patient and data selection criteria and prioritising patient consent and privacy.</div></div><div><h3>Conclusions</h3><div>This secure and extensible imaging and HNC RT cancer database setup promises to be an exceedingly useful tool for research, revolutionising the time and cost associated with the production of ML models, making the process safer, faster and more efficient.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100162"},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144654242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiochemotherapy for salivary gland adenoid cystic carcinoma: survival assessment through a retrospective study exploiting real-world data extracted from data warehouse","authors":"S. Cavalieri ,&nbsp;B. Lombardi Stocchetti ,&nbsp;N. Crippa ,&nbsp;C. Silvestri ,&nbsp;C. Villa ,&nbsp;F. Ghelardi ,&nbsp;P. Baili ,&nbsp;S. Bonfarnuzzo ,&nbsp;I. Cavallo ,&nbsp;N.A. Iacovelli ,&nbsp;M. Franceschini ,&nbsp;A.R. Filippi ,&nbsp;E. Orlandi ,&nbsp;A. Deganello ,&nbsp;V. Cristofaro ,&nbsp;C. Bergamini ,&nbsp;S. Alfieri ,&nbsp;I. Nuzzolese ,&nbsp;E. Colombo ,&nbsp;A. Ottini ,&nbsp;L. Licitra","doi":"10.1016/j.esmorw.2025.100161","DOIUrl":"10.1016/j.esmorw.2025.100161","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Adenoid cystic carcinoma (ACC) is a rare salivary gland malignancy often characterized by an indolent course but significant risk of distant metastasis. The role of concurrent chemoradiotherapy (CRT) in improving oncologic outcomes remains controversial. This study aimed to assess the potential benefits of CRT compared with exclusive radiotherapy (RT) in ACC patients treated with curative intent.</div></div><div><h3>Materials and methods</h3><div>A retrospective cohort study was conducted using real-world data from a tertiary cancer center. Patients with head and neck ACC treated with curative RT between 2007 and 2022 were analyzed. Outcomes were evaluated using Kaplan–Meier and Cox regression analyses. Propensity score matching (PSM) was employed to control for confounding factors. The primary survival outcomes were distant metastasis-free survival (DMFS) and distant metastasis-free interval (DMFI).</div></div><div><h3>Results</h3><div>A total of 178 patients were included (89% receiving surgery), of whom 24 received CRT. Median follow-up was 85.2 months. In the unmatched cohort, CRT showed a trend toward improved DMFS (median 101.38 months versus 50.16 months, <em>P</em> = 0.052) and DMFI (101.38 months versus 53.25 months, <em>P</em> = 0.071). PSM analysis (<em>n</em> = 40) demonstrated statistically significant improvement in DMFI for CRT (median 101.38 months versus 39.8 months, <em>P</em> = 0.032; hazard ratio for distant metastasis 0.43, <em>P</em> = 0.037). No significant differences were observed in overall survival or locoregional control.</div></div><div><h3>Conclusions</h3><div>CRT may delay the onset of distant metastasis and extend DMFI in ACC patients, particularly younger and fit individuals. While overall survival benefits were not observed, these findings support CRT consideration in selected patients. Further prospective studies are warranted to confirm these results.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100161"},"PeriodicalIF":0.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}